The TRR UbiQancer aims to find new approaches for the treatment of selected tumor diseases through a better understanding of the role of the ubiquitin system in cancer.
“UbiQancer will boost the drug discovery pipeline via establishing the necessary synergies amongst the involved research centers. Our group is proud to represent the TUM medicinal chemistry community in the network. The project’s preparation has already impacted our research towards the development of innovative gold-based proteolysis targeting chimeras (PROTACs) as anticancer treatments,” says Prof. Angela Casini (Chair of Medicinal and Bioinorganic chemistry, Dept. of Chemistry).
UbiQancer is in the scope of the new TUM Center for Smart Drug Design (CSDD).
See also: